Hearing loss clinical trials

Explore recruiting hearing loss clinical trials.

Recruiting hearing loss studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Hearing loss trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Phase 1/2 Trial of AAVAnc80-hOTOF Gene Therapy in Individuals with Sensorineural Hearing Loss due to Biallelic Otoferlin Gene (OTOF) Mutations

Spain

Phase I and Phase II (Integrated)- First administration to humans EU CTIS Study details

Extracellular Vesicle-enriched Secretome Fraction (VSF1.01) for the Reduction of Cochlear Implant Surgery Related Trauma (ESCRT). An open-label monocentric phase I/IIa pilot study to investigate the safety of intracochlear application of VSF1.01 enriched with hUC-MSC-EVs in patients receiving cochlear implantation.

Germany

Phase I and Phase II (Integrated)- First administration to humans EU CTIS Study details

Transtympanic sodium thiosulfate to prevent cisplatin-related hearing loss, a randomized controlled multicenter phase III trial; The SOUND trial

Netherlands

Therapeutic confirmatory (Phase III) EU CTIS Study details

Phase IIa randomized, double-blind, and placebo-controlled multicenter split body trial to determine safety, tolerability, and efficacy of repeated doses of ACOU085 for the prevention of hearing loss in testicular cancer patients receiving cisplatin

Germany

Therapeutic exploratory (Phase II) EU CTIS Study details

A double-blind, placebo-controlled, randomised phase 1/2a study to evaluate the safety, tolerability and pharmacokinetics of single and repeated subcutaneous ascending-doses of DX243 in healthy volunteers followed by an extension to assess 1-month safety and preliminary efficacy in patients with mild age-related hearing loss.

Belgium

Phase I and Phase II (Integrated)- First administration to humans EU CTIS Study details

An Evaluation of the Long Term Safety and Efficacy of AAVAnc80-hOTOF Gene Therapy in Individuals with Sensorineural Hearing Loss due to Otoferlin Gene (OTOF) Mutations

Spain

Phase II and Phase III (Integrated) EU CTIS Study details

Hearing loss trials by city

Hearing loss in Toronto Hearing loss in Vancouver Hearing loss in Montreal Hearing loss in Calgary Hearing loss in Edmonton Hearing loss in Ottawa Hearing loss in Winnipeg Hearing loss in Quebec City Hearing loss in Hamilton Hearing loss in Kitchener Hearing loss in London Hearing loss in Halifax Hearing loss in New York Hearing loss in Los Angeles Hearing loss in Chicago Hearing loss in Houston

Other conditions

Hepatitis C COVID-19 Influenza RSV Sickle cell disease Anemia Hemophilia Thalassemia Chronic pain Low back pain Smoking cessation Tinnitus Chronic fatigue syndrome Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism